Latest News

2020

09 November, 2020 Press Releases Press Releases 2020
Amphivena Presents Clinical Update and Translational Data of AMV564 in Solid Tumor Patients at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
23 June, 2020 Press Releases Press Releases 2020
Amphivena Presents Translational Data for its Lead Clinical Candidate, AMV564 at the AACR 2020 Virtual Annual Meeting II
17 June, 2020 Press Releases Press Releases 2020
Amphivena Announces Upcoming Oral Presentation at AACR Virtual Annual Meeting II
29 May, 2020 Press Releases Press Releases 2020
Amphivena Presents Data from First-in-Human Study of AMV564 in Solid Tumor Patients at the ASCO Virtual Annual Meeting 2020
28 May, 2020 Press Releases Press Releases 2020
Amphivena Therapeutics to Present at the Jefferies Virtual Healthcare Conference
14 May, 2020 Press Releases Press Releases 2020
Clinical Data for Amphivena Therapeutics’ Lead Program to be presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

2019

2018

03 December, 2018 Press Releases Press Releases 2018
Amphivena Presents at ASH First-in -Human Phase 1 Clinical Data on AMV564

2017

2016

10 August, 2016 Press Releases Press Releases 2016
Amphivena Therapeutics Announces Acceptance of Investigational New Drug (IND) Application for AMV564 and Planned Phase 1 Trial Initiation

2015